[go: up one dir, main page]

AU2001265119A1 - Naaladase inhibitors for treating amyotrophic lateral sclerosis - Google Patents

Naaladase inhibitors for treating amyotrophic lateral sclerosis

Info

Publication number
AU2001265119A1
AU2001265119A1 AU2001265119A AU6511901A AU2001265119A1 AU 2001265119 A1 AU2001265119 A1 AU 2001265119A1 AU 2001265119 A AU2001265119 A AU 2001265119A AU 6511901 A AU6511901 A AU 6511901A AU 2001265119 A1 AU2001265119 A1 AU 2001265119A1
Authority
AU
Australia
Prior art keywords
lateral sclerosis
amyotrophic lateral
treating amyotrophic
naaladase inhibitors
naaladase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001265119A
Inventor
Barbara S. Slusher
Krystyna Wozniak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai Corp of North America
Original Assignee
Guilford Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guilford Pharmaceuticals Inc filed Critical Guilford Pharmaceuticals Inc
Publication of AU2001265119A1 publication Critical patent/AU2001265119A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2001265119A 2000-05-30 2001-05-30 Naaladase inhibitors for treating amyotrophic lateral sclerosis Abandoned AU2001265119A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20731900P 2000-05-30 2000-05-30
US60/207,319 2000-05-30
PCT/US2001/017325 WO2001091738A2 (en) 2000-05-30 2001-05-30 Naaladase inhibitors for treating amyotrophic lateral sclerosis

Publications (1)

Publication Number Publication Date
AU2001265119A1 true AU2001265119A1 (en) 2001-12-11

Family

ID=22770034

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001265119A Abandoned AU2001265119A1 (en) 2000-05-30 2001-05-30 Naaladase inhibitors for treating amyotrophic lateral sclerosis

Country Status (3)

Country Link
US (1) US20020013295A1 (en)
AU (1) AU2001265119A1 (en)
WO (1) WO2001091738A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105159B1 (en) 1992-11-05 2006-09-12 Sloan-Kettering Institute For Cancer Research Antibodies to prostate-specific membrane antigen
US6953668B1 (en) 1992-11-05 2005-10-11 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen
US7070782B1 (en) 1992-11-05 2006-07-04 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen
US6569432B1 (en) * 1995-02-24 2003-05-27 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen and uses thereof
JP2001526522A (en) 1995-02-24 2001-12-18 スローン−ケタリング・インスティテュート・フォー・キャンサー・リサーチ Prostate specific membrane antigen and uses thereof
US20040253246A1 (en) * 1996-02-23 2004-12-16 Israeli Ron S. Prostate-specific membrane antigen and uses thereof
MXPA03006467A (en) * 2001-01-17 2004-01-29 Guilford Pharm Inc Thiol-based naaladase inhibitors.
EP1392648A1 (en) * 2001-05-11 2004-03-03 Guilford Pharmaceuticals Inc. Hydroxamic acids and acyl hydroxamines as naaladase inhibitors
DK1406867T3 (en) * 2001-05-30 2009-04-06 Eisai Corp North America Thiolalkylbenzoic acid derivatives
EP2360169B1 (en) * 2001-10-23 2015-10-14 Psma Development Company, L.L.C. PSMA antibodies
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
GB2390539A (en) * 2002-07-08 2004-01-14 Pantherix Ltd Tri-substituted benzene & pyridine derivatives with 2 or 3 carboxy-comprising substituents for use as antibiotic or antibacterial agents
SI1599461T1 (en) * 2003-03-03 2009-10-31 Eisai Corp Of North Amarica THIOLACTONES AS NAALADase INHIBITORS
EP2338892A1 (en) 2009-12-18 2011-06-29 Bayer Schering Pharma Aktiengesellschaft Prostate specific membrane antigen inhibitors
CA2986611C (en) * 2015-06-15 2023-10-03 Nmd Pharma Aps Compounds for use in treating neuromuscular disorders
US11730714B2 (en) 2017-12-14 2023-08-22 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US11591284B2 (en) 2017-12-14 2023-02-28 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US11147788B2 (en) 2017-12-14 2021-10-19 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US12440477B2 (en) 2017-12-14 2025-10-14 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054444A (en) * 1997-04-24 2000-04-25 Guilford Pharmaceuticals Inc. Phosphonic acid derivatives
US6384022B1 (en) * 1996-06-17 2002-05-07 Guilford Pharmaceuticals Inc. Prodrugs of NAALAdase inhibitors
US5962521A (en) * 1997-04-04 1999-10-05 Guilford Pharmaceuticals Inc. Hydroxamic acid derivatives
PL332413A1 (en) * 1996-09-27 1999-09-13 Guilford Pharm Inc Compositions containing inhibitors of naaladase as well as methods of treating glutamatic anomaly and influencing neuronic functions among animals
US6028216A (en) * 1997-12-31 2000-02-22 Guilford Pharmaceuticals Inc. Asymmetric syntheses and intermediates for preparing enantiomer-enriched hydroxyphosphinyl derivatives
US6121252A (en) * 1998-03-30 2000-09-19 Guilford Pharmaceuticals Inc. Phosphinic acid derivatives
KR100672965B1 (en) * 1998-07-06 2007-02-28 길포드 파마슈티컬스 인코포레이티드 Naaladase Inhibitors and Compositions thereof Useful as Pharmaceutical Compounds
AU2001265111A1 (en) * 2000-05-30 2001-12-11 Guilford Pharmaceuticals Inc. Benzenedicarboxylic acid derivatives

Also Published As

Publication number Publication date
WO2001091738A2 (en) 2001-12-06
WO2001091738A3 (en) 2002-09-06
US20020013295A1 (en) 2002-01-31

Similar Documents

Publication Publication Date Title
AU2001265119A1 (en) Naaladase inhibitors for treating amyotrophic lateral sclerosis
AU2001258771A1 (en) -secretase inhibitors
AU2001238369A1 (en) Method for treating thyroid disorders
GB9912961D0 (en) Metalloprotease inhibitors
AUPQ859000A0 (en) Apparatus for surface engineering
AU2002219555A1 (en) VLA-4 Inhibitors
AU2001258784A1 (en) Tyrosine phosphatase inhibitors
AU2001234088A1 (en) TNF-alpha inhibitors
AU2002211663A1 (en) Nf-$g(k)b inhibitors
AU2002214163A1 (en) Pyridyl-substituted triazoles as tgf inhibitors
MXPA03006467A (en) Thiol-based naaladase inhibitors.
IL145085A0 (en) Dihetero-substituted metalloprotease inhibitors
AU2001236052A1 (en) Urease inhibitors
AU2001259218A1 (en) Substituted phenyl farnesyltransferase inhibitors
AU2002211662A1 (en) Nf-kappab inhibitors
AU2001234730A1 (en) Method for inhibiting complement activation
AUPR152100A0 (en) Method for treating coral
AU2608301A (en) Methods for inhibiting mastocytosis
EG24462A (en) Compounds for treating fundic disaccomodation
AU2001220281A1 (en) Rollerboard for road-skiing
AU2002211563A1 (en) Compounds useful for treating hypertriglyceridemia
AU2001290710A1 (en) Method for increasing the effectiveness of antiinfective agents
AU2001232245A1 (en) Tnf- alpha inhibitors
AU2002326991A1 (en) Methods for treating multiple sclerosis
AU2001265425A1 (en) Compositions for treating biofilm